Micromet Announces Presentations on BiTE Antibody Programs at AACR Annual Meeting
8:00 am ET 03/22/2010 - PR Newswire
BETHESDA, Md., March 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that 11 presentations will be made by the Company and its collaborators at the American Association for Cancer Research (AACR) 101st Annual Meeting to be held April 17-21, 2010 in Washington, DC.
Presentation details:Poster Title: "Validation of Cynomolgus monkeys as relevant species for safetyassessment of a novel human BiTE antibody platform for cancer therapy"Presentation Date/Time: Monday, April 19, 2010, 2 ??“ 5 PM ETPresenter: Benno Rattel, MicrometAbstract Number: 2435Location: Exhibit Hall A ??“ C, Poster Session 18Poster Title: "Evidence of a therapeutic window with a T cell-engaging BiTEantibody based onmonoclonal antibody cetuximab (Erbitux)"Presentation Date/Time: Monday, April 19, 2010, 2 ??“ 5 PM ETPresenter: Ralf Lutterbuese, MicrometAbstract Number: 2429Location: Exhibit Hall A ??“ C, Poster Session 18Poster Title: "Novel primate-crossreactive BiTE antibodies that eliminatecancer cells expressingcMet, IGFR-1, FAP-alpha, PSCA, endosialin, CAIX or Her2/neu"Presentation Date/Time: Monday, April 19, 2010, 2 ??“ 5 PM ETPresenter: Tobias Raum, MicrometAbstract Number: 2434Location: Exhibit Hall A ??“ C, Poster Session 18Poster Title: "Eradication of established pancreatic tumors in mice byengagement of extra-tumoralhuman T cells with BiTE antibody MT110"Presentation Date/Time: Monday, April 19, 2010, 2 ??“ 5 PM ETPresenter: Matthias Friedrich, MicrometAbstract Number: 2433Location: Exhibit Hall A ??“ C, Poster Session 18Poster Title: "The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds anonlinear epitope present in the full-length but not a short splice variant ofCEA"Presentation Date/Time: Monday, April 19, 2010, 2 ??“ 5 PM ETPresenter: Li Peng, MedImmuneAbstract Number: 2584Location: Exhibit Hall A ??“ C, Poster Session 24Poster Title: "Inhibition of breast cancer cell proliferation and uniqueepitoperecognition by EpCAM-specific human monoclonal antibody adecatumumab"Presentation Date/Time: Wednesday, April 21, 2010, 8 ??“ 11 AM ETPresenter: Markus Muenz, MicrometAbstract Number: 5339Location: Exhibit Hall A ??“ C, Poster Session 19Poster Title: "Impact of binding epitope and antigen size on the cytotoxicactivity of MCSP-specific BiTE antibodies for treatment of melanoma"Presentation Date/Time: Wednesday, April 21, 2010, 8 ??“ 11 AM ETPresenter: Claudia Bluemel, MicrometAbstract Number: 5340Location: Exhibit Hall A ??“ C, Poster Session 19Poster Title: "Metastatic colorectal cancer cells from patients previouslytreated with chemotherapyare sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engagingBiTE antibody"Presentation Date/Time: Wednesday, April 21, 2010, 8 ??“ 11 AM ETPresenter: Takuya Osada, Duke UniversityAbstract Number: 5338Location: Exhibit Hall A ??“ C, Poster Session 19Poster Title: "MCSP/CD3 bispecific single-chain antibody construct engages CD4+and CD8+ T cells for lysis of MCSP-expressing human uveal melanoma cells"Presentation Date/Time: Wednesday, April 21, 2010, 8 ??“ 11 AM ETPresenter: Jacobus Bosch, Erlangen UniversityAbstract Number: 5621Location: Exhibit Hall A ??“ C, Poster Session 31Poster Title: "In vitro and in vivo pharmacology of MEDI-565 (MT111), a novelCEA/CD3-bispecific single-chain BiTE antibody for the treatment ofgastrointestinaladenocarcinomas"Presentation Date/Time: Wednesday, April 21, 2010, 8 ??“ 11 AM ETPresenter: Stacey Fuhrmann, MedImmune, LLCAbstract Number: 5625Location: Exhibit Hall A ??“ C, Poster Session 31Poster Title: "Single-chain bispecific BiTE antibody specific for CD3 andmelanoma-associated chondroitin sulfate proteoglycan: In vitro and in vivoanti-melanoma activity"Presentation Date/Time: Wednesday, April 21, 2010, 8 ??“ 11 AM ETPresenter: Hans Schoellhammer, John Wayne Cancer CenterAbstract Number: 5626Location: Exhibit Hall A ??“ C, Poster Session 31
Abstracts can be accessed through the AACR website, www.aacr.org. All posters will be accessible from Micromet's website at www.micromet-inc.com after they are presented.
About BiTE Antibodies
BiTE?® antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.
About Micromet |
